Amgen is a cornerstone biotech stock representing one of the industry's most successful companies, with a deep pipeline of biologic therapies, a proven track record of bringing innovative medicines to market, and the scale to invest billions annually in research and development across multiple therapeutic areas.
Amgen is developing MariTide, a promising next-generation obesity drug candidate that could compete in the rapidly growing weight loss therapeutics market alongside Eli Lilly and Novo Nordisk.
Data updated Feb 15 · Source: Twelve Data
Amgen is one of the world's largest and most established biotechnology companies, offering investors a rare combination of biotech innovation with large-cap stability. The stock has shown impressive momentum, up 25.5% over 90 days and trading near its 52-week high, well above its 50-day moving average of $338. At a P/E of 22.0 with EPS of $16.76, the valuation is reasonable for a diversified biotech of this caliber. Amgen's deep pipeline, anchored by blockbusters like Repatha and Prolia, provides durable revenue streams. The company's entry into the weight loss space with MariTide (AMG 133), a novel bispecific antibody targeting GIP/GLP-1 receptors, represents a significant growth catalyst, though it remains in mid-stage trials and faces stiff competition from Eli Lilly and Novo Nordisk. Bull case: diversified portfolio, strong cash flows, promising obesity pipeline, and shareholder-friendly capital returns. Bear case: patent cliffs on legacy drugs, high debt levels from the Horizon Therapeutics acquisition, and execution risk in the crowded obesity market. A solid core biotech holding with meaningful optionality.
Amgen (AMGN) stands as a titan in the biotechnology sector, offering a rare blend of blue-chip stability and high-growth potential. Trading near its 52-week high with a P/E ratio of 21.39, the valuation reflects market optimism surrounding its pipeline, particularly its entry into the lucrative obesity drug market with MariTide. The recent acquisition of Horizon Therapeutics further diversifies its revenue streams beyond legacy blockbusters. Unlike many volatile biotech peers, Amgen provides significant financial health and reliable cash flows, supporting a consistent dividend. However, risks remain regarding patent cliffs for aging drugs like Enbrel and the fierce competition within the GLP-1 weight-loss space. For investors looking for exposure to biotech innovation without the extreme volatility of clinical-stage companies, Amgen represents a robust, albeit fully valued, long-term hold.
Latest from Otrai
Every trader has a strategy that looks great in their head. Backtesting is how you find out whether it actually works. Here is how to test strategies properly, what metrics matter, and why most backtest results are too good to be true.
A risk-reward ratio compares how much you stand to lose on a trade to how much you stand to gain. It is arguably the most important number in your trading plan, because it determines whether your strategy can survive a normal losing streak.
Every month, a handful of economic data releases move the forex market more in five minutes than most sessions move in five days. Non-Farm Payrolls, CPI prints, and central bank rate decisions create violent spikes, whipsaws, and trend shifts that can make or break a trading account.
A CFD is a contract between you and your broker to exchange the difference in an asset's price from when you open the trade to when you close it. You never own the underlying asset. That single distinction shapes everything about how CFDs work, what they cost, and why regulators treat them differently from traditional investing.
Powered by Rexiew